이 보고서는 발기부전(ED)에 대한 상세한 분석을 제공하며 총 유병자 수, 진단된 유병자 수, 연령 및 병인별 환자 수, 치료 환자 수 등 과거 및 미래의 역학 데이터를 제시합니다. 또한 진단 프로세스, 처방 패턴, 의사의 견해, 시장 접근, 치료 옵션, 시장 전망 동향을 미국, EU 4개국(독일, 프랑스, 이탈리아, 스페인), 영국, 일본의 주요 7개국 시장에 걸쳐 2020-2034년 기간으로 분석했습니다. 또한 기존의 치료실태와 미충족 수요(Unmet Needs)를 종합적으로 평가하여 시장의 잠재력과 새로운 사업 기회를 명확히 하고 있습니다.
DelveInsight's comprehensive report titled "Erectile Dysfunction- Market Insights, Epidemiology, and Market Forecast - 2034" offers a detailed analysis of Erectile Dysfunction. The report presents historical and projected epidemiological data covering total prevalent cases of Erectile Dysfunction, total diagnosed prevalent cases of Erectile Dysfunction, age-specific cases of Erectile Dysfunction, etiology-specific cases of Erectile Dysfunction and treated cases of Erectile Dysfunction. In addition to epidemiology, the market report encompasses various aspects related to the patient population. These aspects include the diagnosis process, prescription patterns, physician perspectives, market accessibility, treatment options, and prospective developments in the market across seven major markets: the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning from 2020 to 2034.
The report analyzes the existing treatment practices and unmet medical requirements in Erectile Dysfunction. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the market.
Erectile Dysfunction Overview
Erectile dysfunction, previously known as impotence, refers to the consistent inability to achieve or maintain a firm penile erection sufficient for satisfactory sexual intercourse. Although some definitions suggest the condition must persist for at least six months, it commonly affects men over the age of 40 and becomes more prevalent with aging and comorbidities such as diabetes, hypertension, and cardiovascular disease. It may result from impaired blood flow, nerve damage, hormonal imbalances, or structural problems in penile tissue, with endothelial dysfunction often playing a central role.
While most cases of erectile dysfunction stem from physical causes, psychological factors may contribute, especially in younger individuals. Regardless of the underlying cause, the condition frequently leads to emotional distress, reduced self-esteem, strained relationships, and overall decreased quality of life for both the individual and their partner. As such, erectile dysfunction has significant medical and psychosocial implications.
Erectile Dysfunction Diagnosis and Treatment Algorithm
Identifying psychogenic causes of erectile dysfunction, especially in younger men, is crucial and can often be distinguished by sudden onset, situational dysfunction, normal morning or solo erections, or recent life changes. While most cases are organic, psychological support is often beneficial regardless of the cause, helping address anxiety, relationship stress, and treatment adherence. Mental health referrals should be normalized as part of routine care, much like any other diagnostic evaluation.
Initial evaluation does not require extensive testing; basic labs like complete blood count (CBC), metabolic panel, lipid profile, and morning testosterone may be done. Additional tests-such as penile biothesiometry, nocturnal tumescence testing, and penile Doppler ultrasound-are optional and used in selected cases to differentiate between vascular or neurological causes or to evaluate trauma-related dysfunction.
Erectile dysfunction is initially managed through lifestyle changes-such as exercise, a healthy diet, and addressing underlying conditions like diabetes or hypertension-along with psychological support when needed. First-line treatment typically involves oral phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil), which are effective in many men but require sexual stimulation.
For those who do not respond, options include alprostadil (administered intraurethrally or via injection), testosterone therapy in hypogonadal men, topical agents like Eroxon, and vacuum erection devices. Surgical implants offer a long-term solution for refractory cases. Experimental therapies like shockwave therapy, stem cells, and platelet-rich plasma remain under investigation.
The epidemiology section of the Erectile Dysfunction market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.
This section also presents the data with relevant tables and graphs, offering a clear and concise view of the prevalence of Erectile Dysfunction. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.
Key Findings
According to secondary sources, available data suggests that approximately 52% of men in the United States aged 40 to 70 experience erectile dysfunction. Overall, it is estimated that 30 to 50 million men in the US have erectile dysfunction.
According to secondary source, the prevalence of erectile dysfunction in men (age group 20 to 79 years) in Japan is approximately 30.9%, affecting around 14 million men.
As per secondary source, the prevalence of erectile dysfunction in Germany is approximately 21%, based on population data assessing male sexual dysfunctions.
The Erectile Dysfunction therapeutics market is further expected to increase by the major drivers, such as the rising prevalence population, technological advancements, and upcoming therapies in the forecast period (2025-2034).
With ongoing research and continued dedication, the future holds hope for even more effective treatments and, ultimately, a cure for this challenging condition. According to DelveInsight, the Erectile Dysfunction market in the 7MM is expected to change significantly during the forecast period 2025-2034.
Emerging Erectile Dysfunction Drugs
The Erectile Dysfunction market is expected to evolve gradually, driven by the limited number of emerging therapies currently in development. Key players such as Bremelanotide + PDE5i, by Palatin Technologies, among others are showing active commitment to addressing this unmet need, with ongoing efforts to advance novel treatment options for this complex condition.
Bremelanotide + PDE5i: Palatin Technologies
Palatin has created a new single-injection co-formulation combining bremelanotide with a PDE5 inhibitor for the treatment of erectile dysfunction. The company plans to submit an Investigational New Drug (IND) application to the FDA later this year, with a potential Phase III trial targeting patients who do not respond to PDE5 inhibitor monotherapy.
In June 2024, Palatin Technologies announced the initiation of a Phase II clinical study of bremelanotide (BMT), a melanocortin 4 receptor (MC4R), co-administered with a phosphodiesterase 5 inhibitor (PDE5i), for the treatment of erectile dysfunction in patients that do not respond to PDE5i monotherapy.
Erectile Dysfunction Market Segmentation
DelveInsight's 'Erectile Dysfunction - Market Insights, Epidemiology, and Market Forecast - 2034' report provides a detailed outlook of the current and future Erectile Dysfunction market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.
Erectile Dysfunction Market Size by Countries
The Erectile Dysfunction market size is assessed separately for various countries, including the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. In 2024, the United States held a significant share of the overall 7MM (Seven Major Markets) Erectile Dysfunction market, primarily attributed to the country's higher prevalence of the condition and the elevated cost of the available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.
This section focuses on the sales uptake of potential Erectile Dysfunction drugs that have recently been launched or are anticipated to be launched in the Erectile Dysfunction market between 2020 and 2034. It estimates the market penetration of Erectile Dysfunction drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the Erectile Dysfunction market.
The emerging Erectile Dysfunction therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the Erectile Dysfunction market.
Erectile Dysfunction Market Access and Reimbursement
DelveInsight's 'Erectile Dysfunction- Market Insights, Epidemiology, and Market Forecast - 2034' report provides a descriptive overview of the market access and reimbursement scenario of Erectile Dysfunction.
This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.
KOL Views
To keep up with current Erectile Dysfunction market trends and fill gaps in secondary findings, we interview KOLs and SMEs' working in the Erectile Dysfunction domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or Erectile Dysfunction market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the Erectile Dysfunction unmet needs.
Erectile Dysfunction: KOL Insights
DelveInsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as University of Minnesota Medical School, US, University of Ulm, Germany, University of Malaga, Spain, Nancy University, France, University of Birmingham, UK, and Osaka University Graduate School of Medicine Center, Japan, among others.
"Erectile function is controlled by a complex network involving primary afferents, spinal interneurons, and autonomic nerves. Neurological disorders can interfere with this regulation by impacting the endocrine or cardiovascular systems, and neuropathy, whether central or peripheral, is a known contributor to erectile dysfunction."
"It's important to distinguish between erectile dysfunction and premature ejaculation, as men may misreport symptoms. A man with premature ejaculation might claim erectile issues due to early loss of erection, while one with erectile dysfunction may report premature ejaculation from rushing to climax. Though often confused, both conditions can also occur simultaneously."
"Diabetes is a major risk factor for erectile dysfunction, with evidence from both human and animal studies dating back to the 1970s. Chronic high blood sugar may impair nitric oxide production, disrupt the cGMP pathway, increase oxidative stress, activate the RhoA/Rho kinase pathway, and damage nerves. These mechanisms are believed to contribute to ED in diabetic patients."
Competitive Intelligence Analysis
We conduct a Competitive and Market Intelligence analysis of the Erectile Dysfunction Market, utilizing various Competitive Intelligence tools such as SWOT analysis and Market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.
Erectile Dysfunction Pipeline Development Activities
The report offers an analysis of therapeutic candidates in Phase II and III stages and examines companies involved in developing targeted therapeutics for Erectile Dysfunction. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.
Pipeline Development Activities
The report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging Erectile Dysfunction therapies.
The main goals are to restore erectile function, improve sexual satisfaction and quality of life, and address underlying physical or psychological causes. Management also involves treating comorbidities, reducing distress, minimizing treatment side effects, and encouraging a healthy lifestyle to prevent progression.
Managing erectile dysfunction is challenging due to its multifactorial causes, including vascular, neurological, hormonal, and psychological factors. Distinguishing between organic and psychogenic components requires careful evaluation. Long-term management is further complicated by comorbidities such as diabetes and cardiovascular disease, limited access to specialized care or advanced treatments, and issues with adherence, stigma, and treatment expectations. These factors can hinder effective, sustained improvement.
Key factors driving the growth of the erectile dysfunction market include increased awareness and reduced stigma surrounding men's sexual health, along with a rising prevalence of associated conditions such as diabetes, hypertension, and cardiovascular disease. Advances in oral pharmacotherapy, including next-generation PDE5 inhibitors and alternative delivery systems, have broadened treatment accessibility. Additionally, growing interest in regenerative therapies, improved healthcare access, and expanding telemedicine services are further accelerating market growth.
The report will provide comprehensive insights into the current Erectile Dysfunction market landscape, emerging therapies, competitive dynamics, regulatory requirements, and market access considerations, enabling informed decision-making, strategic planning, and optimization of business strategies to capitalize on market opportunities and drive growth.
3.1.. Market Share (%) Distribution by Therapies in 2024
3.2.. Market Share (%) Distribution by Therapies in 2034
7.1.. Introduction
7.3.. Causes
7.4.. Pathophysiology
7.5.. Symptoms
7.6.. Risk Factor
7.7.. Diagnosis
7.7.1.. Diagnostic Algorithm
7.7.2.. Diagnostic Guidelines
7.8.. Treatment and Management
7.8.1.. Treatment Algorithm
7.8.2.. Treatment Guidelines
11.8.. Japan Market Size